Vitae Pharmaceuticals Inc. (VTAE) announced positive results from its Phase 2a proof-of-concept clinical trial of VTP-43742 in psoriatic patients after the bell Wednesday. VTP-43742 demonstrated a clear signal of efficacy.
from RTT - Before the Bell http://ift.tt/258zrtY
via IFTTT
No comments:
Post a Comment